NTRA - ナテラ （Natera Inc.） ナテラNTRAのチャート
NTRAの企業情報
| symbol | NTRA |
|---|---|
| 会社名 | Natera Inc （ナテラ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ナテラ(Natera Inc.)は診断会社である。同社は遺伝子検査サービスの発見・開発・商品化に従事する。同社は、母親から採血した胎児の染色体異常をスクリーニングするパノラマ非侵襲性出生前検査、キャリアの子供に渡される可能性のある多数の重度の遺伝病のキャリアステータスを決定するホライゾンキャリアスクリーニング、体外受精サイクル中に染色体異常または遺伝的遺伝的状態を分析して健康な子供になる可能性のある胚を選択するスペクトラムプレ移植遺伝子スクリーニングとスペクトラムプレ移植遺伝子診断、流産の原因を理解するために胎児の染色体を分析する受胎テストのAnora製品、並びに妊娠している母親の血液中の胎児性デオキシリボ核酸の断片と、疑わしい父親由来の血液サンプルを分析することにより父性を決定する非侵襲性父性検査を提供する。 ナテラは米国の遺伝子検査サ―ビス会社。主に出生前の遺伝子検査を提供する。体外受精において、着床前遺伝子スクリ―ニングを提供し、染色体異常や遺伝性遺伝子の状態を解析することで、受精胚の選択を可能にする。また、胎児の染色体異常を発見する検査や実父確定検査なども提供する。本社はカリフォルニア州サンカルロス。 Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA. |
| 本社所在地 | 201 Industrial Road Suite 410 San Carlos CA 94070 USA |
| 代表者氏名 | Matthew Rabinowitz マシュー・ラビノウィッツ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Co-Founder |
| 電話番号 | +1 650-249-9090 |
| 設立年月日 | 37926 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 893人 |
| url | www.natera.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ntra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -120.49200 |
| 終値（lastsale） | 21.31 |
| 時価総額（marketcap） | 1298720475.8 |
| 時価総額 | 時価総額（百万ドル） 1225.587 |
| 売上高 | 売上高（百万ドル） 235.83000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1265.723 |
| 当期純利益 | 当期純利益（百万ドル） -139.31800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Natera Inc revenues increased 23% to $125.4M. Net loss increased 7% to $66.7M. Revenues reflect United States segment increase of 21% to $107M Europe Middle East India Africa segment increase of 91% to $13.1M. Higher net loss reflects Interest and other income decrease from $887K (income) to $3.8M (expense) Interest expense increase from $401K to $4.9M (expense). |
NTRAのテクニカル分析
NTRAのニュース
Natera to Present New Gastrointestinal Cancer Data at the ESMO Annual Meeting 2020/09/18 13:03:00 PR Newswire
SAN CARLOS, Calif., Sept. 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized molecular residual disease (MRD) test, Signatera, at the 2020 European Society for Medical…
Natera Announces Pricing of Follow-On Offering 2020/09/11 04:53:00 PR Newswire
SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 4,166,666 shares of its common stock at a price to the public of $60.00 per share. Closing of the…
Natera to Present at the Morgan Stanley 18th Annual Global Healthcare Conference 2020/09/10 18:41:00 PR Newswire
SAN CARLOS, Calif., Sept. 10, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will webcast a live presentation at the Morgan Stanley 18th Annual Global Healthcare Conference taking place virtually on Monday, Sept….
Natera Launches Proposed Follow-On Offering 2020/09/09 21:07:00 PR Newswire
SAN CARLOS, Calif., Sept. 9, 2020 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of shares of its common stock. In addition, Natera expects to grant the underwriters…
Natera Receives Final Medicare Coverage for its Signatera™ MRD Test in Stage II-III Colorectal Cancer 2020/09/03 14:37:00 PR Newswire
SAN CARLOS, Calif., Sept. 3, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the CMS Molecular Diagnostics Program (MOLDX) has finalized a local coverage determination (LCD) to provide Medicare benefits for…
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat 2020/07/22 11:24:35 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer COVID-19 diagnostics testing to the NFL) ResMed Inc. (NYSE: RMD ) Retrophin Inc (NASDAQ: RTRX ) Trevena Inc (NASDAQ: TRVN ) Twist Bioscience Corp (NASDAQ: TWST ) Veracyte Inc (NASDAQ: VCYT ) West Pharmaceutical Services Inc.
Orange tops Egypt’s mobile data service providers in May 2020/07/15 09:52:59 Mubasher Info (Feed)
Cairo – Mubasher: Orange Egypt topped mobile operators in data services in Egypt in May for the 11th month in a row, according to a report released by the National Telecom Regulatory Authority (NTRA). The average data speed of Orange Egypt reached …
Natera Recognized as a 'Force for Change' by Leading Women Entrepreneurs (LWE) 2020/07/14 13:03:00 PR Newswire
SAN CARLOS, Calif., July 14, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has received the Force for Change Illuminator award from LWE, accepted by Sheetal Parmar, Natera's VP of Medical Affairs. The Force for Change awards are…
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts 2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
Natera : Amendment to a previously filed 4 | MarketScreener 2020/06/23 13:02:07 MarketScreener
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check… | June 23, 2020
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts 2020/07/02 12:21:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1) AbbVie Inc (NYSE: ABBV ) ADC Therapeutics SA (NYSE: ADCT ) Affimed NV (NASDAQ: AFMD ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akero Therapeutics Inc (NASDAQ: AKRO ) ( announced positive results for mid-stage study of NASH drug) Amgen, Inc. (NASDAQ: AMGN ) (reacted to a favorable court ruling on its Enbrel patent litigation) Aptinyx Inc (NASDAQ: APTX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP ) Crispr Therapeutics AG (NASDAQ: CRSP ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Legend Biotech Corp (NASDAQ: LEGN ) Liminal BioSciences Inc (NASDAQ: LMNL ) (announced commencement of convalescent plasma collection from donors who have recovered from COVID-19 and upcoming catalysts) Natera Inc (NASDAQ: NTRA ) Opko Health Inc. (NASDAQ: OPK ) Pacira Biosciences Inc (NASDAQ: PCRX ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) Twist Bioscience Corp (NASDAQ: TWST ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) (announced FDA approval for drug to treat long-chain fatty acid oxidation disorders) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 1) ADiTx Therapeutics Inc (NASDAQ: ADTX ) Fusion Pharmaceuticals Inc (NASDAQ: FUSN ) Generation Bio Co (NASDAQ: GBIO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Repare Therapeutics Inc (NASDAQ: RPTX ) Stocks In Focus Novartis Finalizes $678M Settlement In US Lawsuit Over Kickbacks Paid To Doctors Novartis AG (NYSE: NVS ) said it has finalized its previously disclosed agreement with the U.S.
Natera : Amendment to a previously filed 4 | MarketScreener 2020/06/23 13:02:07 MarketScreener
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check… | June 23, 2020
Natera Expands Lab Footprint With State-Of-The-Art Facility in Austin, Texas 2020/06/22 13:03:00 PR Newswire
SAN CARLOS, Calif., June 22, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, is pleased to announce the expansion of its laboratory facility in Austin, Texas, supporting greater test processing capacity. This newly expanded, 70,000…
Natera Announces First Patient Enrollments in Both CIRCULATE-Japan and BESPOKE CRC Trials Using Signatera™ MRD Testing 2020/06/18 13:05:00 Benzinga Feeds
SAN CARLOS, Calif. , June 18, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA ), a pioneer and global leader in cell-free DNA testing, today announced that enrollment has begun in the CIRCULATE-Japan and BESPOKE CRC trials, with both studies experiencing strong interest from centers across Japan and the U.S. The studies will measure clinical outcomes of Signatera molecular residual disease (MRD) testing in resectable Stages II-IV colorectal cancer (CRC). The CIRCULATE-Japan trial, organized by the National Cancer Center (NCC) Japan , is a prospective, multi-center, randomized trial that will investigate optimal circulating tumor DNA (ctDNA)-guided treatment strategies for patients with resectable Stage II-IV CRC, particularly adjuvant chemotherapy decisions based on MRD status. The study will include 2,500 patients from approximately 150 cancer centers across Japan . The NCC's recent announcement on the official launch of the CIRCULATE-Japan trial can be found here. "We are encouraged to see the trial gaining so much early momentum, and we see a great opportunity ahead to improve treatment decisions for the thousands of CRC patients in Japan , and worldwide, who may not benefit from adjuvant chemotherapy," said the study's Principal Investigator, Dr.